{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:10:48Z","timestamp":1789726248449,"version":"4.0.1"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.seizure.2020.12.016","type":"journal-article","created":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T20:47:50Z","timestamp":1610570870000},"page":"119-126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Efficacy and tolerability of fenfluramine in patients with Dravet syndrome: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7003-7218","authenticated-orcid":false,"given":"Indar Kumar","family":"Sharawat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7831-9271","authenticated-orcid":false,"given":"Prateek Kumar","family":"Panda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananthanarayanan","family":"Kasinathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pragnya","family":"Panda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesa","family":"Dawman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kriti","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2020.12.016_bib0005","first-page":"e5006","article-title":"Dravet syndrome: an overview","volume":"11","author":"Anwar","year":"2019","journal-title":"Cureus"},{"key":"10.1016\/j.seizure.2020.12.016_bib0010","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.pediatrneurol.2020.01.005","article-title":"Dravet syndrome: a review of current management","volume":"107","author":"Wheless","year":"2020","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.seizure.2020.12.016_bib0015","first-page":"68","article-title":"Letter: Fenfluramine approved by F.D.A. in America","volume":"20","author":"Parker","year":"1974","journal-title":"Cent Afr J Med"},{"issue":"166","key":"10.1016\/j.seizure.2020.12.016_bib0020","first-page":"168","article-title":"The fenfluramine\/phentermine combination for weight loss","volume":"22","author":"Garrett","year":"1997","journal-title":"Nurse Pract"},{"key":"10.1016\/j.seizure.2020.12.016_bib0025","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/0920-1211(88)90044-7","article-title":"Dopamine agonist treatment of self-induced pattern-sensitive epilepsy. A case report","volume":"2","author":"Clemens","year":"1988","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2020.12.016_bib0030","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJM198511283132219","article-title":"Treatment of self-induced photosensitive epilepsy with fenfluramine","volume":"313","author":"Aicardi","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seizure.2020.12.016_bib0035","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/BF01487068","article-title":"Compulsive respiratory stereotypies in children with autistic features: polygraphic recording and treatment with fenfluramine","volume":"17","author":"Gastaut","year":"1987","journal-title":"J Autism Dev Disord"},{"key":"10.1016\/j.seizure.2020.12.016_bib0040","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1046\/j.1528-1157.2002.casa432.x","article-title":"Fenfluramine as a potential antiepileptic drug","volume":"43","author":"Casaer","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2020.12.016_bib0045","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1055\/s-2007-973781","article-title":"Add-on therapy of fenfluramine in intractable self-induced epilepsy","volume":"27","author":"Boel","year":"1996","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.seizure.2020.12.016_bib0050","article-title":"Fenfluramine and dexfenfluramine withdrawn from market","volume":"54","year":"1997","journal-title":"Am J Health-Syst Pharm AJHP Off J Am Soc Health-Syst Pharm"},{"key":"10.1016\/j.seizure.2020.12.016_bib0055","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s40263-020-00755-z","article-title":"Fenfluramine for the treatment of dravet syndrome and Lennox\u2013Gastaut syndrome","volume":"34","author":"Balagura","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/j.seizure.2020.12.016_bib0060","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1471-2288-14-45","article-title":"Newcastle-Ottawa Scale: comparing reviewers\u2019 to authors\u2019 assessments","volume":"14","author":"Lo","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.seizure.2020.12.016_bib0065","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1398-9995.2009.01973.x","article-title":"Grading quality of evidence and strength of recommendations in clinical practice guidelines. Part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions","volume":"64","author":"Brozek","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.seizure.2020.12.016_bib0070","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.seizure.2020.12.016_bib0075","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/j.1528-1167.2012.03495.x","article-title":"Successful use of fenfluramine as an add-on treatment for Dravet syndrome","volume":"53","author":"Ceulemans","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2020.12.016_bib0080","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1111\/epi.13407","article-title":"Five-year extended follow-up status of 10 patients with Dravet syndrome treated with fenfluramine","volume":"57","author":"Ceulemans","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2020.12.016_bib0085","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/S0140-6736(19)32500-0","article-title":"Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial","volume":"394","author":"Lagae","year":"2019","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.seizure.2020.12.016_bib0090","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1001\/jamaneurol.2019.4113","article-title":"Fenfluramine for treatment-resistant seizures in patients with Dravet syndrome receiving stiripentol-inclusive regimens: a randomized clinical trial","volume":"77","author":"Nabbout","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.seizure.2020.12.016_bib0095","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1177\/1756285615607726","article-title":"Low-dose fenfluramine in the treatment of neurologic disorders: experience in Dravet syndrome","volume":"8","author":"Schoonjans","year":"2015","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.seizure.2020.12.016_bib0100","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/epi.16474","article-title":"Successful use of fenfluramine in nonconvulsive status epilepticus of Dravet syndrome","volume":"61","author":"Specchio","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2020.12.016_bib0105","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/ene.13195","article-title":"Low-dose fenfluramine significantly reduces seizure frequency in Dravet syndrome: a prospective study of a new cohort of patients","volume":"24","author":"Schoonjans","year":"2017","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.seizure.2020.12.016_bib0110","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5414\/CP203276","article-title":"A phase I, randomized, open-label, single-dose, 3-period crossover study to evaluate the drug-drug interaction between ZX008 (fenfluramine HCl oral solution) and a regimen of stiripentol, clobazam, and valproate in healthy subjects","volume":"57","author":"Boyd","year":"2019","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.seizure.2020.12.016_bib0115","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1177\/1060028019856008","article-title":"Stiripentol: a novel antiseizure medication for the management of dravet syndrome","volume":"53","author":"Buck","year":"2019","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.seizure.2020.12.016_bib0120","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1111\/epi.14540","article-title":"A pilot, open-label study of the effectiveness and tolerability of low-dose ZX008 (fenfluramine HCl) in Lennox-Gastaut syndrome","volume":"59","author":"Lagae","year":"2018","journal-title":"Epilepsia"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131120304131?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131120304131?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:57:50Z","timestamp":1761011870000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131120304131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":24,"alternative-id":["S1059131120304131"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2020.12.016","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and tolerability of fenfluramine in patients with Dravet syndrome: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2020.12.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 British Epilepsy Association. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}